Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 11/20 | 0.87 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | BMP1 | P13497 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 1/20 | 0.72 |
| ▸ | TACR1 | P25103 | 1/20 | 0.65 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2415823 | 0.98 | NMBR (0.87) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2382811 | 0.97 | NMBR (0.85) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2382050 | 0.97 | NMBR (0.85) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2370414 | 0.97 | NMBR (0.85) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2421029 | 0.97 | NMBR (0.85) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2417077 | 0.97 | NMBR (0.85) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2370248 | 0.97 | NMBR (0.85) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2420021 | 0.97 | NMBR (0.85) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2416371 | 0.97 | NMBR (0.85) | NMBRMAPTGAAHTTLMNA | |
| SCHEMBL2417039 | 0.96 | NMBR (0.90) | NMBRMAPTGAAHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224124-A1 | pH Tuneable Amido-Gellant For Use In Consumer Product Compositions | THE PROCTER & GAMBLE COMPANY | 2011-09-15 | — | — | US | claimed |
| WO-2011112912-A1 | PH TUNEABLE AMIDO-GELLANT FOR USE IN CONSUMER PRODUCT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2011-09-15 | — | — | WO | claimed |
| EP-2365052-A1 | pH tuneable-gellant for use in consumer product compositions | The Procter & Gamble Company (US) | 2011-09-14 | — | — | EP | claimed |
| EP-2365052-A1 | pH tuneable-gellant for use in consumer product compositions | The Procter & Gamble Company (US) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224124-A1 | pH Tuneable Amido-Gellant For Use In Consumer Product Compositions | AGPAT2, AGPAT5, GNAO1 | NMBR 401/4885MAPT 1301/4885GAA 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.